Investors

2026 Second quarter results announcement

We will announce our second quarter 2026 results on 28 July at 12:00 BST, 07:00 EDT.

Quarterly results Register for the webcast

Who we are

As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.

Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

Purpose, strategy and culture

Why invest in GSK?

Respiratory, immunology and inflammation

deaths each year due to lung diseases

Go to respiratory, immunology and inflammation

Oncology

~10m

people die from cancer each year

Go to oncology

HIV

40m

people living with HIV globally

Go to HIV

Infectious diseases

1 in 7

deaths globally caused by infectious disease

Go to infectious diseases

Behind the Science

Exploring how today's discoveries are shaping tomorrow's health

'I had dreams': How HIV care has evolved across a generation

'Long-acting options are the future to prevent transmission of HIV'

‘It’s always there’: Learning to live with chronic hepatitis B

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

Antibody-drug conjugates: Advancing the search for more targeted cancer treatment

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

Read our magazine

INVESTORS

We will announce our second quarter 2026 results on Tuesday 28 July

View latest results